We and others have shown that selectively targeting IL-23 prevents auto-immune inflammation in experimental models of MS [9], inflammatory bowel disease [10], [11] and in a clinically relevant psoriasis model [12]. This evidence concerns the gene IL23A and myeloid sarcoma.